BC
SRPT icon

Birchview Capital’s Sarepta Therapeutics SRPT Stock Holding History

Birchview Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,500
Closed -$426K – 70
2024
Q4 		$426K Buy
3,500
+1,000
+40% +$123K 0.35% 37
2024
Q3 		$312K Hold
2,500
– – 0.27% 45
2024
Q2 		$395K Hold
2,500
– – 0.37% 36
2024
Q1 		$324K Hold
2,500
– – 0.26% 44
2023
Q4 		$241K Hold
2,500
– – 0.19% 48
2023
Q3 		$303K Hold
2,500
– – 0.26% 40
2023
Q2 		$286K Hold
2,500
– – 0.21% 46
2023
Q1 		$345K Hold
2,500
– – 0.27% 39
2022
Q4 		$324K Hold
2,500
– – 0.23% 42
2022
Q3 		$276K Buy
+2,500
New +$252K 0.19% 49

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Birchview Capital's SRPT Position: Q1 2025 in Review

Birchview Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 3,500 shares — an estimated $426K sold.

Birchview Capital first reported a position in SRPT in Q3 2022 and held it in 10 quarters. The position peaked at $426K in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Birchview Capital reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Birchview Capital sold 3,500 Sarepta Therapeutics shares in Q1 2025, an estimated $426K.
  • Birchview Capital first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 10 quarters.
  • Birchview Capital's Sarepta Therapeutics position peaked at $426K in Q4 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Birchview Capital's 13F filing for Q1 2025, filed 15 May 2025.